A Neurotrophic Peptide Boosted New Brain Cell Growth by 80% and Restored Memory After Brain Injury

Adult C57BL/6 mice received controlled cortical impact injuries with 1.5 mm of cortical penetration to model mild to moderate TBI. Animals were then treated with either Peptide 6 (50 nmol/day) or saline for 30 days. Researchers quantified dentate gyrus neurogenesis, dendritic and synaptic density, and Alzheimer's disease biomarkers (hyperphosphorylated tau and amyloid-beta) using confocal microscopy and immunohistochemistry. Memory was assessed using behavioral tests.

There are currently no approved drugs that promote brain repair after traumatic brain injury. Peptide 6 is notable because it doesn't just prevent further damage — it actively promotes the growth of new neurons and rebuilds lost synaptic connections, addressing the root problem rather than just managing symptoms. The connection between TBI and Alzheimer's biomarkers makes this doubly relevant, as treating TBI-related damage could potentially reduce Alzheimer's risk.

Peptide 6 belongs to a growing class of neurotrophic peptides — small molecules derived from natural brain growth factors that can cross the blood-brain barrier and promote neural repair. While full-length growth factors like CNTF and BDNF are too large to use as drugs, peptide fragments that capture their active regions offer a more practical therapeutic approach. This study bridges TBI research and Alzheimer's prevention, two fields increasingly recognized as connected.

This is a mouse study using a controlled injury model that may not fully replicate the diversity of human TBI. The sample size is not specified in the abstract. The 30-day treatment window started immediately after injury, which may not reflect the delayed treatment scenarios common in clinical practice. Long-term effects beyond 30 days are unknown. The peptide's ability to cross the blood-brain barrier in humans and its pharmacokinetics have not been characterized.